The week’s biggest announcement was WuXi AppTec’s sale of WuXi Advanced Therapies, its cell and gene therapy unit, to U.S.-based private equity firm Altaris.
This year, the sector saw a record number of U.S. approvals, with high expectations for the clinical pipeline in 2025. But companies like bluebird bio face major hurdles.
